Vivozon Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	3,138	6,525	7,987	2,351	13,799
Short-Term Investments	2,020	2,211	5,330	11,600	14,880
Trading Asset Securities	-	1,252	4,404	12,448	35,376
Cash & Short-Term Investments	5,158	9,988	17,721	26,400	64,055
Cash Growth	-48.36%	-43.64%	-32.88%	-58.79%	-29.36%
Accounts Receivable	9,739	11,900	-	8,847	10,712
Other Receivables	355.87	368.04	-	347.19	2,428
Receivables	10,223	14,409	-	9,694	13,163
Inventory	15,849	19,637	12,994	11,199	16,034
Prepaid Expenses	826.97	269.57	-	20.8	421.39
Other Current Assets	1,482	103.33	14,423	248.44	2,659
Total Current Assets	33,539	44,407	45,138	47,562	96,333
Property, Plant & Equipment	26,272	31,814	25,521	33,968	32,807
Long-Term Investments	86,284	94,560	91,484	95,242	45,857
Other Intangible Assets	3,686	4,190	4,631	5,574	8,612
Long-Term Accounts Receivable	0	-0	-	-	-
Long-Term Deferred Tax Assets	-	-	-	-	3,431
Long-Term Deferred Charges	14,716	7,864	6,209	3,437	2,880
Other Long-Term Assets	984.37	1,614	662.93	1,006	653.97
Total Assets	165,481	184,449	173,647	187,074	194,471
Accounts Payable	7,765	11,827	10,632	6,152	6,622
Accrued Expenses	1,564	1,575	1,532	1,848	2,167
Short-Term Debt	40,929	34,476	39,996	52,572	67,993
Current Portion of Long-Term Debt	-	-	-	5,604	867.11
Current Portion of Leases	878.7	1,182	624.62	653.17	610.93
Current Income Taxes Payable	-	30.1	-	-	-
Current Unearned Revenue	1,851	1,906	3,504	3,685	3,685
Other Current Liabilities	24,724	21,215	8,490	8,746	7,078
Total Current Liabilities	77,712	72,211	64,779	79,261	89,023
Long-Term Debt	-	-	-	-	13,958
Long-Term Leases	533.97	841.95	994.18	1,481	685.36
Pension & Post-Retirement Benefits	4,060	3,807	2,600	1,809	2,288
Long-Term Deferred Tax Liabilities	972.12	923.51	923.51	927.93	1,823
Other Long-Term Liabilities	9,538	238.67	283.74	130.07	150.4
Total Liabilities	92,816	78,022	69,580	83,609	107,928
Common Stock	125,262	125,262	120,529	117,022	84,953
Additional Paid-In Capital	250,604	249,419	245,296	243,684	216,611
Retained Earnings	-303,792	-271,829	-261,313	-257,365	-216,914
Treasury Stock	-10.05	-13.12	-18.19	-	-
Comprehensive Income & Other	601.24	3,588	-427.4	125.39	469.82
Total Common Equity	72,665	106,427	104,067	103,466	85,120
Minority Interest	-	-	-	-	1,422
Shareholders' Equity	72,665	106,427	104,067	103,466	86,542
Total Liabilities & Equity	165,481	184,449	173,647	187,074	194,471
Total Debt	42,341	36,500	41,615	60,310	84,115
Net Cash (Debt)	-37,183	-26,512	-23,894	-33,910	-20,060
Net Cash Per Share	-751.13	-555.09	-500.74	-779.45	-615.13
Filing Date Shares Outstanding	49.51	49.38	47.21	46.81	33.98
Total Common Shares Outstanding	49.51	49.38	47.21	46.81	33.98
Working Capital	-44,173	-27,804	-19,640	-31,699	7,310
Book Value Per Share	1467.54	2155.28	2204.51	2210.40	2504.91
Tangible Book Value	68,979	102,237	99,436	97,892	76,508
Tangible Book Value Per Share	1393.10	2070.44	2106.41	2091.33	2251.47
Land	6,037	6,037	6,037	6,037	6,183
Buildings	10,694	6,835	6,678	6,557	7,886
Machinery	23,766	23,153	23,401	20,015	22,216
Construction In Progress	47.23	7,598	1,943	12,132	9,142

Source: S&P Global Market Intelligence. Standard template. Financial Sources.